The purpose of this study is to evaluate the safety and efficacy of zipalertinib in combination with standard first-line platinum-based chemotherapy compared to chemotherapy alone, in patients with locally advanced or metastatic NSCLC with EGFR ex20ins mutations.
Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
The purpose of this study is to evaluate the safety and efficacy of zipalertinib in combination with standard first-line platinum-based chemotherapy compared to chemotherapy alone, in patients with locally advanced or metastatic NSCLC with EGFR ex20ins mutations.
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
-
Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada, United States, 89052
Comprehensive Cancer Centers of Nevada - Horizon Ridge Henderson, Henderson, Nevada, United States, 89052
Comprehensive Cancer Centers of Nevada - Southeast Henderson - Stephanie, Henderson, Nevada, United States, 89074
Comprehensive Cancer Centers of Nevada - Summerlin Medical Center II, Las Vegas, Nevada, United States, 89144
Comprehensive Cancer Centers of Nevada - Southwest, Las Vegas, Nevada, United States, 89148
Comprehensive Cancer Centers of Nevada - Central Valley - Twain, Las Vegas, Nevada, United States, 89169
Comprehensive Cancer Centers of Nevada - Northwest, Las Vegas, Nevada, United States, 89218
Gabrail Cancer and Research Center, Canton, Ohio, United States, 44718
The Toledo Clinic Cancer Center, Toledo, Ohio, United States, 43623
University of Texas MD Anderson Cancer Center, Houston, Texas, United States, 77030
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Taiho Oncology, Inc.,
2026-08-24